Research programme: RNA therapeutics - Riboxx Pharmaceuticals
Alternative Names: Apoxxim; RGC 1; RGC L1; RGC L2; RGIC 1; RIBOXXIM®; RIBOXXON®Latest Information Update: 28 Mar 2020
At a glance
- Originator Riboxx Pharmaceuticals
- Developer Riboxx Pharmaceuticals; TOLLYS SAS
- Class Drug conjugates; RNA
- Mechanism of Action DDX58 protein modulators; Toll-like receptor 3 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Autoimmune disorders; Cancer; Viral infections
Highest Development Phases
- No development reported Autoimmune disorders; Cancer; Viral infections
Most Recent Events
- 28 Mar 2020 No recent reports of development identified for preclinical development in Cancer in France
- 28 Mar 2020 No recent reports of development identified for preclinical development in Cancer in Germany
- 28 Mar 2020 No recent reports of development identified for preclinical development in Viral-infections in Germany